| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 50.00▲ | 50.00▲ | 49.99▲ | 49.96▲ | 50.06▼ |
| MA10 | 50.02▲ | 50.02▲ | 50.02▲ | 49.98▲ | 50.09▼ |
| MA20 | 50.05▼ | 50.06▼ | 50.06▼ | 50.03▼ | 50.12▼ |
| MA50 | 50.12▼ | 50.11▼ | 50.11▼ | 50.09▼ | 50.35▼ |
| MA100 | 50.19▼ | 50.19▼ | 50.19▼ | 50.12▼ | N/A |
| MA200 | 50.34▼ | 50.38▼ | 50.39▼ | 50.32▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.003▲ | 0.003▲ | -0.002▼ | 0.001▲ | -0.003▼ |
| RSI | 48.716▼ | 48.578▼ | 48.650▼ | 49.294▼ | 45.212▼ |
| STOCH | 50.876 | 50.876 | 43.099 | 42.092 | 41.757 |
| WILL %R | -41.538 | -41.538 | -41.538 | -49.824 | -65.269 |
| CCI | -2.469 | -2.469 | 11.984 | 64.534 | -120.638▼ |
|
Monday, December 15, 2025 05:14 AM
(RTTNews) - Dimerix Limited (DXB.AX) has completed adult patient enrolment in its pivotal ACTION3 Phase 3 trial of DMX-200 for focal segmental glomerulosclerosis, successfully dosing its 286th patient ...
|
|
Wednesday, April 30, 2025 04:20 PM
Dimerix Limited has granted Amicus Therapeutics exclusive rights to commercialize its drug candidate DMX-200 in the U.S. for Focal Segmental Glomerulosclerosis (FSGS), a serious kidney disease that ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 07/08/26 | 50.03 | 50.09 | 50.01 | 50.0306 | 9,521 |
| 06/08/26 | 49.98 | 50.06 | 49.97 | 49.9783 | 4,593 |
| 05/08/26 | 50.00 | 50.03 | 49.94 | 49.9744 | 13,850 |
| 04/08/26 | 49.93 | 49.9799 | 49.93 | 49.9586 | 8,774 |
| 03/08/26 | 49.86 | 49.88 | 49.86 | 49.87 | 8,525 |
| 31/07/26 | 50.00 | 50.0502 | 49.99 | 50.0502 | 3,449 |
| 30/07/26 | 49.99 | 50.11 | 49.99 | 50.045 | 8,253 |
| 29/07/26 | 50.00 | 50.015 | 49.95 | 49.9551 | 6,715 |
| 28/07/26 | 49.9593 | 50.0099 | 49.9593 | 49.99 | 3,224 |
| 27/07/26 | 50.00 | 50.00 | 49.95 | 49.96 | 8,285 |
|
|
||||
|
|
||||
|
|